Summary
NSCLC accounts for nearly 80–85% of all lung cancer cases. Among these patients, HER2 mutations are identified in roughly 1–4% of cases.
ENHERTU became the first FDA-approved therapy for unresectable/metastatic HER2 (ERBB2)-mutant NSCLC in 2022; however, along with recently approved HERNEXEOS and HYRNUO, treatment remains largely limited to the second-line setting, highlighting a persistent unmet need in first-line HER2-mutant NSCLC.
Potential drugs in the pipeline include Pyrotinib (Jiangsu HengRui Medicine), FWD1509 (Forward Pharmaceuticals), IAM1363 (Iambic Therapeutics), EO-1001 (Edisononcology), and others in different stages of clinical develo...
